colorectal cancer
Conditions
Interventions
Aprepitant cohort (Administer a triple antiemetic regimen of aprepitant injection, ondansetron, and dexamethasone):None
Non-aprepitant cohort (Administer a dual antiemetic regimen of ondansetron, and dexamethasone):None
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1)=18 years old; (2)Histologically confirmed as colorectal cancer; (3)The patients are preparing to receive the first-line mFOLFOX6 regimen combined with cetuximab biweekly; (4)Patients receive a triple or dual regimen for the prevention of chemotherapy related nausea and vomiting; (5)The patient/family member signed an informed consent form and voluntarily participated in this study.
Exclusion criteria
Exclusion criteria: (1)Receive NK-1 receptor antagonist one week before enrollment; (2)Oral antifungal medication 4 weeks before enrollment or topical antifungal medication 2 weeks before enrollment; (3)The patients have a skin infection or dermatitis; (4)Patients who are allergic to any medication used in this study; (5)Using drugs that are prohibited from being used in combination with aprepitant; (6)Patients who are currently or plan to participate in other clinical studies; (7)Researchers determine other situations that are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of pruritus; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time and severity of pruritus;The incidence, timing, and severity of rash;Safety of medication;quality of life of the patients; | — |
Countries
China
Contacts
Public ContactQingwei Zhao
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed